Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats

Advanced Pharmaceutical Bulletin

Volumn 2, Issue 2, 2012, Pages 149-155

  Mahmoudi, Javad ^a   Nayebi, Alireza Mohajjel ^b,c   Reyhani Rad, Siyamak ^d   Samini, Morteza ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Catalepsy; Fluoxetine; L dopa; Motor imbalance; Rat

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; FLUOXETINE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; NONHUMAN; RAT; ROTAROD TEST; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874967509     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2012.023     Document Type: Article

References (31)

1. Chen Q, He Y, Yang K. Gene Therapy for Parkinson's disease: Progress and Challenges. Curr Gene Ther 2005;5:71-80.
2. 1A receptor agonists in alleviating motor symptoms of Parkinson's disease. Afr J Pharm Pharmacol 2010;4:4289-90.
3. Orth M, Tabrizi SJ. Models of Parkinson's disease. Mov Disord 2003;18:729-37.
4. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat Disord 2008;14:154-8.
5. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162:1-10.
6. 1A receptors in rats. Pharmacol Rep 2010;62:258-64.
7. Kalda A, Herm L, Rinken A, Zharkovsky A, Chen JF. Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice. Behav Brain Res 2009;202:232-7.
8. Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA. Nitric oxide synthase inhibition attenuatesL-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuroscience 2009;159:927-35.
9. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Serotonin-dopamine interaction in induction and maintenance of L-DOPA-induced dyskinesias. In: Progress in brain research. Di Giovanni G, Di matteo V, Esposito E, editors. Elsevier BV; 2008. 465-78.
10. Maeda T, Kannari K, Huo S, Arai A, Tomiyama M, Matsunaga M, et al. Increase of the striatal serotonergic fibers after nigrostriatal dopaminergic denervation in adult rats. Int Congr Ser 2003;1251:211-5.
11. Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006;99:381-92.
12. Mahmoudi J, Nayebi AM, Samini M, Reyhani-Rad S, Babapour V. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. Pharm rep 2011;63:908-14.
13. 1B receptor the treatment of L-DOPA-induced dyskinesia. Brain 2008;131:3380-94.
14. Ulusoy A, Sahin G, Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci USA 2010;107:13159-64.
15. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-33.
16. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. J Neurosci 2007;27:8011-22.
17. 1A receptor agonist 8-OH-DAPT in a rat model of levodopa-induced motor complication. Brain Res 2007;1127:177-84.
18. Matteo VD, Pierucci M, Esposito E, Crescimanno G, Benigno A, Giovanni GD. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for parkinsons disease and other motor disorders. Prog brain Res 2008;172:423-63.
19. 1A receptors. DARU 2010;18:41-5.
20. Mohajjel Nayebi A, Reyhani-Rad S, Mahmoudi J, Samini M. Effect of fluoxteine on motor disorders induced by intranigral injection of 6-hydroxydopamine in rats. Pharm Sci 2010;16:45-54.
21. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Academic press; 1982.
22. 1A receptor activation improves anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats. Daru 2011;19:338-43.
23. Sharma N, Rana AC, Bafan P. Effect of aqueous extract of cynodondactylon on reserpine induced catalepsy. Int J Pharm Pharm Sci 2011;3:424-6.
24. Meredith GE, Sonsalla PK, Chesselet MF. Animal models of Parkinson disease progression. Acta Neuropathol 2008;115:385-98.
25. 1A receptor agonist prevents behavioral sensitization to L-DOPA in rodent model of Parkinson's disease. Neurosci Res 2005;52:185-94.
26. Pires JG, Bonikovski V, Futuro-Neto HA. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res 2005;38:1867-72.
27. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids. Proc Natl Acad Sci USA 2004;101:6222-5.
28. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereo specifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl). 2006;186:362-72.
29. Dekundy A, Lundblad M, Danysz W, Cenci MA. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 2007;179:76-89.
30. 1A agonist buspirone reduces the expression and development of L-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy. Pharmacol Biochem Behav 2007;87:306-14.
31. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-92.